Trials / Completed
CompletedNCT04158817
68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage
Gallium-68 Labelled THP-PSMA for the Clinical Stage and Restage of Prostate Cancer Patients
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- Male
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the dosimetry, safety and the detection rate of 68Ga-THP-PSMA PET/CT for identifying the site of prostate cancer metastasis and relapse. It is also to evaluate the association of clinical/pathologic features and 68Ga-THP-PSMA PET/CT detection rate and compare 68Ga-THP-PSMA PET/CT with other imaging procedure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga-Labeled PSMA | All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection. |
| DRUG | Non-labeled PSMA | Patient will be injected with microdose (\<100 ug) of THP-PSMA |
Timeline
- Start date
- 2019-11-01
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
- First posted
- 2019-11-12
- Last updated
- 2023-04-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04158817. Inclusion in this directory is not an endorsement.